PRNewsWire
13 Oct 2026, 11:45 UTC · 1h ago
Impact · against what's priced in
TuHURA Biosciences gains a modest valuation lift as new patent coverage broadens the utility and exclusivity of TBS-2025 beyond oncology into autoimmune and infection treatments. This expands the asset's long-term appeal for M&A and reduces binary risk ahead of Phase 1b AML data.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
The USPTO issued Patent No. 12,760,104 broadening coverage for TBS-2025 to include bispecific/multi-specific antibodies across all classes of human antibodies.
Newpress release dated Oct 13, 2026
So whatExpanded IP coverage increases the asset's valuation for potential corporate collaborators or M&A targets before the Phase 1b data readout.
More positive than 87% of claims this week
Continue reading
5 related stories
The issuance of Patent No. 12,760,104 extends exclusivity for TBS-2025 to 2042 and expands the potential addressable market into autoimmune diseases and infection, increasing the asset's strategic value for potential collaborators.
Read from the article alone
Scored by the NIS engine · methodology.
The new patent claims expand the potential use of TBS-2025 beyond cancer into treatment areas for autoimmune disease and infection.
Newpress release dated Oct 13, 2026
So whatDiversifying the Total Addressable Market (TAM) beyond oncology reduces the binary risk associated with the current Phase 1b AML trial.
More positive than 66% of claims this week
The patent term for TBS-2025 extends to February 18, 2042.
Newpress release dated Oct 13, 2026
So whatThis provides roughly 15 years of exclusivity beyond the typical 10-year window from a hypothetical 2027 approval.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company received a new U.S. patent that broadens coverage for its VISTA inhibitor, TBS-2025, extending protection and potential therapeutic applications.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
13h ago
—
HURA hasn't traded since this ran. Last close $1.90 (Oct 12); the reaction starts at the next open.
HURA chart →
